Advances toward structure-based drug discovery for inflammasome targets
Open Access
- 16 November 2021
- journal article
- research article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 219 (1)
- https://doi.org/10.1084/jem.20211147
Abstract
Inflammasome proteins play an important role in many diseases of high unmet need, making them attractive drug targets. However, drug discovery for inflammasome proteins has been challenging in part due to the difficulty in solving high-resolution structures using cryo-EM or crystallography. Recent advances in the structural biology of NLRP3 and NLRP1 have provided the first set of data that proves a promise for structure-based drug design for this important family of targets.Funding Information
- National Institutes of Health
This publication has 13 references indexed in Scilit:
- Structural and biochemical mechanisms of NLRP1 inhibition by DPP9Nature, 2021
- DPP9 sequesters the C terminus of NLRP1 to repress inflammasome activationNature, 2021
- Inhibiting the NLRP3 InflammasomeMolecules, 2020
- Activation of the CARD8 Inflammasome Requires a Disordered RegionCell Reports, 2020
- The NLRP1 Inflammasome in Human Skin and BeyondInternational Journal of Molecular Sciences, 2020
- Structural mechanism for NEK7-licensed activation of NLRP3 inflammasomeNature, 2019
- The NLRP3 inflammasome: molecular activation and regulation to therapeuticsNature Reviews Immunology, 2019
- Inflammasome signalling in brain function and neurodegenerative diseaseNature Reviews Neuroscience, 2018
- An Update on Autoinflammatory Diseases: InflammasomopathiesCurrent Rheumatology Reports, 2018
- Inflammasomes and Their Roles in Health and DiseaseAnnual Review of Cell and Developmental Biology, 2012